News

AV-101 Reduces Parkinson’s Dyskinesia Without Amantadine Side Effects, Preclinical Study Suggests

VistaGen Therapeutics’ candidate, AV-101, reduced levodopa-induced dyskinesia (abnormal involuntary movements) while maintaining levodopa activity in a non-human primate model of Parkinson’s disease. Importantly, AV-101 treatment did not cause the adverse side effects observed with amantadine, a therapy that works similar to AV-101 to ease Parkinson’s symptoms.

Report Showcases Benefits of Creativity Induced by Levodopa

A new report describes two Indian men with Parkinson’s disease who experienced “creative awakenings” after they started being treated with levodopa. Appropriately titled, “A tale of two patients: Levodopa and creative awakening in Parkinson’s disease – A qualitative report,” the study was published in the Asian Journal…